// App-Quantinova.ai

3039 : Lurbinectedin specifically targets transcription in cancer cells, triggering DNA breaks and degradation of phosphorylated Pol II

Researchers

Presenter

  • Gema Santamaria-Nunez

Principal Investigators

  • Carlos M. Genes-Robles

  • Juan F. Martinez-Leal

  • Carlos M. Galmarini

  • Jean Marc Egly

Medical Centers

  • PharmaMar, Madrid, Spain

  • Institut de Genetique et de Biologie Moleculaire et Cellulaire, Illkirch, France.

Locations

  • France

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Small cell lung cancer

  • Gynaecological cancer

  • Breast cancer

  • Solid malignancies

  • Lung Cancer

Biomarkers

  • Cyclin dependent kinase 7

  • ERCC Excision Repair 4, Endonuclease Catalytic Subunit

Drug/Treatment

  • Lurbinectedin

  • Doxorubicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved